Investing.com -- 艾沙株式会社 (Eisai Co.)股价当日上涨0.4%，此前一度下跌，投资者正在消化该公司季度业绩报告，报告显示其阿尔茨海默病药物乐伐替尼 (Leqembi)销售强劲增长。 这家日本制药公司报告称，第一季度乐伐替尼全球销售额同比增长269%，达到¥23.1亿。然而，这一令人印象深刻的增长包括来自中国的¥5.3亿一次性需求，这一点此前已在合作伙伴Biogen ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Eli Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after over three years of treatment.

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

Long-term treatment with lecanemab shows slowed progression of early Alzheimer’s disease, according to data presented at the ...

With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...